Cyclacel Pharmaceuticals Undergoes Leadership Change as New CEO Takes the Helm

Cyclacel Pharmaceuticals, Inc. has announced a major leadership and ownership transition following the acquisition of a controlling stake by Datuk Dr. Doris Wong Sing Ee. Under a Securities Purchase Agreement, Dr. Wong acquired 70% of Cyclacel’s issued and outstanding shares for $6.3 million, making her the new controlling shareholder. The transaction, which closed on February 26, 2025, led to significant structural changes, including the resignation of interim CEO David Lazar and several board members. As part of the transition, Kiu Cu Seng has been appointed as Executive Director, Secretary, and Chief Financial Officer.

Expressing enthusiasm for her new role, Dr. Wong stated, “I am honored to serve as Cyclacel’s next CEO and look forward to driving innovation in our biopharmaceutical business.” The company also announced key board appointments, reinforcing its commitment to leadership renewal. With this strategic shift, Cyclacel is poised to enter a new phase of growth, aiming to deliver cutting-edge cancer treatments and generate long-term value for its stakeholders.